Several preclinical and clinical indications have demonstrated that intrinsic or acquired resistance to fluoropyrimidines correlates with low or deficient intratumoral TP expression [6, 7, 43, 44], which suggests that an increase in TP expression might enhance the sensitivity of tumor cells to these drugs. The gene discussed is TYMP; the disease is neoplasm.